Strengthening the corneal stroma by inducing the production of chemical crosslinks within the collagen structure has been shown to be an effective treatment for keratoconus and is currently being investigated as a treatment for low refractive errors.
1,2 The standard, US Food and Drug Administration–approved version of this technique uses ultraviolet-A (UVA) irradiation to excite the photosensitizer, riboflavin (Rf), imbibed into the patient's corneal stroma, causing the production of oxygen free radicals that in turn induce collagen crosslinking (CXL) within the corneal stroma.
3,4 While this technique is clinically successful in causing corneal stiffening and flattening,
1,5–15 it is still far from ideal for many reasons. Chief among these reasons are the low precision of the technique and the method of Rf application.
Keratocyte damage within the volume of CXL is inevitable with this procedure, and endothelial cell damage is a risk in corneas thinner than 400 µm.
16 Unfortunately, the single-photon nature of UVA CXL allows for very little precision with regard to the volume of cornea treated. Even when UVA CXL is customized by altering radiation profiles across the treatment area, the reaction must begin at the surface, covering the entire exposed area of the cornea, and quenches with depth into the stroma.
17 A previously tested technique that improves upon the precision of corneal CXL uses focused femtosecond (FS) infrared laser pulses to produce CXL within a highly defined region, with micron-level precision in every direction. This alternative technique, termed
nonlinear optical crosslinking (NLO CXL), has been shown to produce comparable results to traditional UVA CXL, namely, increased corneal stiffness and the generation of blue collagen autofluorescence due to the formation of collagen crosslinks.
5,6
Another important concern about traditional UVA CXL involves the method of Rf application to the corneal stroma. Because the corneal epithelial barrier function prevents Rf molecules from penetrating into the corneal stroma, traditional UVA CXL requires epithelial debridement. This is painful for the patient, lengthens the recovery time, and exposes the cornea to possible infection.
14,18 The development of transepithelial UVA CXL is a highly active area of research, with many different methods being tested both in the laboratory and clinically. Common methods used to avoid debridement of the epithelium include the addition of chemicals such as benzalkonium chloride (BAK) to weaken epithelial tight junctions,
2,19–23 the addition of vitamin E or C,
24,25 or using iontophoresis during Rf application.
26–29 Whatever the method of Rf application, however, transepithelial UVA CXL has yet to reproduce the results of traditional UVA CXL.
14,23,30–32 Specifically, a review of the literature shows that patients with transepithelial crosslinking show improved Best spectacle corrected visual acuity (BSCVA) compared to traditional crosslinking but do not show a halting of the progression of ectasia.
31 This could be due to the reduced concentration of Rf within the corneal stroma when the epithelium is left intact. It could also be due in part to the nature of the single-photon reaction used, which begins at the surface, in this case within the epithelium itself. That is, the corneal epithelium acts as a barrier not only to Rf penetration but also to the necessary UVA irradiation.
To address both issues, we propose a new method of Rf application to be used in combination with our existing NLO CXL technology. We hypothesized that FS laser-based micromachining of channels through the corneal epithelium would increase Rf penetration into the corneal stroma, avoiding the cellular damage often associated with eye drops containing BAK.
23,33,34 This method would also have the added advantage of being highly compatible with NLO CXL after Rf application, which can produce CXL at any depth and pattern.